Related Experiment Video

Updated: Jun 14, 2026

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.5K

Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

Gilad Sherman1,2, Gabriella S Lamb1,2, Tanvi S Sharma1,2

  • 1Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.

Journal of the Pediatric Infectious Diseases Society
|March 17, 2023
PubMed

Insights

Monoclonal antibody treatments for COVID-19 in high-risk pediatric patients showed low rates of adverse events and hospital admissions. This study provides crucial evidence for the safety and efficacy of these therapies in younger populations.

Area of Science:

  • Pediatric Infectious Diseases
  • Immunology
  • Pharmacology

Background:

  • COVID-19 poses risks to pediatric patients, particularly those with underlying conditions.
  • Monoclonal antibodies are authorized for high-risk individuals aged 12 and older.
  • Limited data exists on monoclonal antibody use in pediatric populations.

Purpose of the Study:

  • To evaluate the safety and effectiveness of monoclonal antibodies in pediatric patients with COVID-19.
  • To assess adverse events, hospital admissions, and severe outcomes within 30 days of treatment.

Main Methods:

  • A retrospective cohort study was conducted across seven pediatric hospitals.
  • Data was collected from 142 pediatric patients treated between December 1, 2020, and July 31, 2021.
  • Outcomes included adverse events, 30-day hospital admissions, need for ventilatory support, and mortality.

Main Results:

  • Of 142 pediatric patients, 9% experienced adverse events.
  • Six percent of patients were admitted for COVID-19 within 30 days of treatment.
  • No patients required ventilatory support, and no deaths were reported.

Conclusions:

  • Monoclonal antibodies appear to be safe and well-tolerated in high-risk pediatric patients with COVID-19.
  • Treatment was associated with low rates of hospitalization and no mortality in this cohort.
  • Further research is warranted to confirm these findings in larger pediatric populations.

Keywords:
COVID-19SARS-CoV-2bamlanivimab and etesevimabcasirivimab and imdevimabmonoclonal antibodiespediatric

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...